Trials / Completed
CompletedNCT04325620
Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease
A Multicenter, Randomized, Parallel, Double-Blinded, Placebo-controlled Phase 3 Study to Compare Efficacy and Safety of HIP1601 in Patients With Non-Erosive Gastroesophageal Reflux Disease(NERD)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 208 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety and clinical efficacy of HIP1601 in patients with Non-erosive gastroesphageal reflux disease.
Detailed description
A Multicenter, Randomized, Parallel, Double-Blinded, Placebo-controlled Phase Ⅲ Study to Compare Efficacy and Safety of HIP1601 in Patients with Non-Erosive Gastroesophageal Reflux Disease(NERD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HIP1601 | HIP1601 |
| DRUG | HGP1805 | Placebo of HIP1601 |
Timeline
- Start date
- 2019-06-10
- Primary completion
- 2020-08-03
- Completion
- 2020-08-03
- First posted
- 2020-03-27
- Last updated
- 2022-11-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04325620. Inclusion in this directory is not an endorsement.